Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Cy5.5-Conjugated anti-epidermal growth factor receptor monoclonal antibody C225

Arvind Chopra  1
In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004.
[updated ].
Affiliations
Free Books & Documents
Review

Cy5.5-Conjugated anti-epidermal growth factor receptor monoclonal antibody C225

Arvind Chopra.
Free Books & Documents

Excerpt

The epidermal growth factor receptor (EGFR) is often overexpressed or constitutively activated in several different cancer types, and these phenotypes are linked to an elevated metastatic potential, which indicates a poor prognosis for the patient (1-3). Because of its role in the development of cancer phenotypes, several anti-EGFR monoclonal antibodies (MAb), which are commercially available or under development and evaluation in clinical trials, have been approved by the United States Food and Drug Administration for the diagnosis and treatment of various cancers (4). It has also been shown that under preclinical (5, 6) and clinical (7) conditions, radioisotope-labeled anti-EGFR MAbs can be used for the diagnosis and treatment of cancers. In addition, as an alternative to the radiolabeled MAbs, anti-EGFR antibodies labeled with infrared fluorescent dyes have also been developed and evaluated in preclinical tumor xenograft models for the detection of cancers overexpressing EGFR, including oral cancer (8-11).

According to the Oral Cancer Foundation, >34,000 Americans will be diagnosed with oral or pharyngeal cancers this year, and among them ~8,000 will die from this condition. Oral cancer, ~90% of which is of the squamous cell carcinoma (SCC) type, is usually discovered at a late stage of development because it produces no pain and shows no symptoms during its early stages. Therefore, early detection of this cancer can result in the development of an appropriate, more aggressive, treatment regimen and increase the chances of a good prognosis. In an effort to produce a dual-purpose agent that could be used for early detection of oral cancer and also to determine the efficacy of an anti-cancer drug, Soukos et al. conjugated C225, an anti-EGFR MAb, to an infrared fluorescent dye, N,N’-di-carboxypentyl-indodicarbocyanine-5,5’-disulfonic acid (Cy5.5), and evaluated the conjugate for early detection of oral cancer in a hamster cheek pouch carcinogen evaluation model (11). The Cy5.5-conjugated MAb (C225-Cy5.5) was also used to monitor treatment of the cancer with chlorine6 (Ce6), a photosensitizer, conjugated to C225 (C225-Ce6), which was used for photodynamic therapy of oral cancer.

PubMed Disclaimer

Similar articles

  • Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo.
    Soukos NS, Hamblin MR, Keel S, Fabian RL, Deutsch TF, Hasan T. Soukos NS, et al. Cancer Res. 2001 Jun 1;61(11):4490-6. Cancer Res. 2001. PMID: 11389080 Free PMC article.
  • Cy5.5 conjugated anti-epidermal growth factor receptor monoclonal antibody.
    Chopra A. Chopra A. 2007 Oct 18 [updated 2007 Nov 1]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Oct 18 [updated 2007 Nov 1]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641853 Free Books & Documents. Review.
  • 111In-DTPA-Poly(ethylene glycol)-anti-epidermal growth factor receptor antibody C225.
    The MICAD Research Team. The MICAD Research Team. 2007 Jun 7 [updated 2007 Jul 2]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Jun 7 [updated 2007 Jul 2]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641771 Free Books & Documents. Review.
  • Epidermal growth factor conjugated to near-infrared fluorescent quantum dots.
    Chopra A. Chopra A. 2009 Feb 2 [updated 2009 Feb 25]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2009 Feb 2 [updated 2009 Feb 25]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641330 Free Books & Documents. Review.
  • IRDye 800-Anti–epidermal growth factor receptor Affibody.
    Leung K. Leung K. 2010 Jun 17 [updated 2010 Sep 9]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2010 Jun 17 [updated 2010 Sep 9]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20845547 Free Books & Documents. Review.
See all similar articles

References

NIH Support

    1. Some studies mentioned in this chapter were supported by National Institutes of Health grant R01 AR40352.

References

    1. Ke S., Wen X., Gurfinkel M., Charnsangavej C., Wallace S., Sevick-Muraca E.M., Li C. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. . Cancer Res. 2003;63(22):7870–5. - PubMed
    1. Garcia J., Riely G.J., Nafa K., Ladanyi M. KRAS mutational testing in the selection of patients for EGFR-targeted therapies. . Semin Diagn Pathol. 2008;25(4):288–94. - PubMed
    1. Laurent-Puig P., Lievre A., Blons H. Mutations and response to epidermal growth factor receptor inhibitors. . Clin Cancer Res. 2009;15(4):1133–9. - PubMed
    1. Mishani E., Abourbeh G., Eiblmaier M., Anderson C.J. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. . Curr Pharm Des. 2008;14(28):2983–98. - PMC - PubMed
    1. Reilly R.M., Kiarash R., Sandhu J., Lee Y.W., Cameron R.G., Hendler A., Vallis K., Gariepy J. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. . J Nucl Med. 2000;41(5):903–11. - PubMed

LinkOut - more resources